@Mezarque
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Cofounder of @dittobio, @ycombinator (W26) | prev: @berkeleyMCB @hscrb
Ohlone Land (Berkeley, CA)
Joined January 2012
- Tweets1.3K
- Following465
- Followers1.5K
- Likes8.2K
Pinned Tweet
Some news: excited to share that I'm building @dittobio with @AdairLBorges and @emilycpierce as part of the @ycombinator W26 batch!
We're discovering drugs for autoimmune disease by harnessing parasite biology.
Shout out @agupta for betting on us. 🔗 below:
We’re launching @trybaseframe to take you from AI fatigued to AI native.
You already have the AI tools. What you don't have is the time to figure out what to actually do with them, which features are useful to you, and how to use them.
BaseFrame does that for you. Its desktop app finds the repetitive work eating your week that you could automate today with the AI tools you already have.
Download the app and start unlocking hours today. Link below:
If you’ve been looking for an Acquired equivalent for biotech, it has arrived and you too can listen below
Dennis Sun retweeted
The genomics revolution told us which genes cause disease.
What if small molecules could target the genetic message? CRISPR-level precision, in a pill.
Endura Insights #1: why the genomics revolution is only half finished.
enduratx.com/blog/the-genomi…
Thrilled to be building with Pioneer!
🧬 @dittobio is utilizing parasite strategies for developing breakthrough drugs for autoimmune disease. Why parasites? They've been running experiments on humans for millions of years being able to control the human immune system. Ditto is building an AI platform to identify drug-like proteins from these types of organisms which they then engineer into safe, effective therapeutics.
🦠 🪲 🪱 They are just getting started and have already analyzed over a million proteins across primate-infecting viruses, ticks, and parasitic worms. Initial discovery is looking promising!
@pioneer_fund is proud to back these three PhD scientists! Congratulations @AdairLBorges, @Mezarque, and @emilycpierce. Excited to partner with you!
Founder multitasking:
- listening to a talk on lipid nanoparticle-mediated immune tolerance…
- while stress-buying domain names and emailing cloud providers to kill a spoofed website.
At @dittobio we copy nature’s playbook to treat disease. 👯
Today, someone tried copying us.
shout out @posthog for helping us notice the spoofer and @GoDaddy @AWSstartups @googlecloud for helping us take them down!
also @Namecheap for being our DNS provider!
don't come at me for my tabs
It’s been an incredible 10 months of science at @dittobio, and I’m excited to share some of our progress in our first blog post.
Today, we're sharing our analysis mapping parasite proteins and human diseases they could treat.
dittobio.com/blog/2025-03-02…
Dennis Sun retweeted
Finally got around to writing up some of our progress at @dittobio !
Check out our inaugural blog post to learn how my favorite parasites (aka viruses 😎) can improve target selection and discover blockbuster drug mechanisms for autoimmune disease:
dittobio.com/blog/2025-03-02…
My @ycombinator puffer is finally fulfilling its true purpose: keeping me warm in the dead of winter.
I’m in Boston this week for the Antigen-Specific Immune Tolerance Summit (as-immunetolerance.com/)!
I’m representing our team at @dittobio – we copy nature’s playbook to build novel therapeutics for autoimmune diseases.
If you’re in Boston and want to meet up, please reach out! I’m excited to talk about platforms, partnerships, and next-gen therapies for autoimmune disease.
My top 2 themes from this year's @Biocom Global Partnering & Investor Conference #BiocomGPIC:
1. AI's impact in drug discovery + development
2. China <> US competition & collaboration
Every panel conversation kept returning to these two areas. More in thread:
1/n
China (cont'd):
- for US companies to stay competitive, capital efficiency is king
- revisions to the regulatory landscape around starting clinical trials (e.g. centralized systems like in AUS/NZ) + improved speed to human evidence could level the playing field
4/n
This was my first time attending. Incredible to hear from luminaries in the field and meet many amazing people working hard to bring new therapies to patients in need.
Thanks to everyone who reached out for a convo / met up!
Follow our work at @dittobio for more :)
Excited to be back home in sunny San Diego for @Biocom's Global Partnering & Investor Conference this week. hashtag #BiocomGPIC
I’m here representing our team at @dittobio, where we’re copying nature’s playbook to build next-gen protein therapeutics for autoimmune disease.
Vapid, grifting, rage bait-driven startups do a disservice to the broader ecosystem b/c the public (+ media class) over-indexes on stories like these.
Most founders I know are good, kind, serious people trying to solve real problems. A shame the grifters get outsized attention
“Until we build an all-powerful but distant God, the agency problem remains. AIs are not capable of directing themselves; most people aren’t either.”
Sam Kriss reports from San Francisco on the next generation of AI technologists.
harpers.org/archive/2026/03/…
